Change in the Number of Shares in Vitrolife AB (publ)
Magnus Nilsson CEO
Vitrolife is a global biotechnology/medical device Group that works with developing, manufacturing and selling advanced products and systems for the preparation, cultivation and storage of human cells, tissue and organs. The company has business activities within three product areas: Fertility, Transplantation and Stem Cell Cultivation.
The Fertility product area works with nutrient solutions (media), cryopreservation products and advanced consumable instruments such as needles and pipettes, for the treatment of human infertility. The Transplantation product area works with solutions and systems to evaluate and maintain organs outside the body order to select usable organs and keeping them in optimal condition while waiting for transplantation. The Stem Cell Cultivation product area works with media and instruments to enable the use and handling of stem cells for therapeutic purposes.
Vitrolife today has approximately 150 employees and the company's products are sold in more than 80 markets. The company is headquartered in Gothenburg, Sweden, and there are subsidiaries in USA, Australia, France and Italy. Production facilities are located in Sweden and USA.
The Vitrolife share is listed on NASDAQ OMX Stockholm, Small Cap.
Vitrolife is required to publish the information in this press release in accordance with the Swedish Securities Market Act and/or the Financial Instruments Trading Act. The information was submitted for publication on Friday May 29, 2009 at 8:30 am CET.
This is a translation of the Swedish version of the notice. When in doubt, the Swedish wording prevails.
This information was brought to you by Cision http://www.cisionwire.com
Contact: Vitrolife AB (publ) Magnus Nilsson, CEO phone +46 31 721 80 61 or Eva NilsagÃ¥rd, CFO Phone +46 31 721 80 13
Posted: May 2009